The Michigan Institute for Clinical & Health Research (MICHR) at the University of Michigan has selected the OpenClinica Enterprise clinical trial software platform to support a growing clinical study portfolio. Starting this fall, MICHR will begin deployment of OpenClinica for a wide variety of clinical trials.
According to Jim Maszatics, Clinical Research Informatics Core (CRIC) Manager at MICHR, OpenClinica offers a robust infrastructure that will enhance MICHR’s competitiveness for extramural funding. “Static budgets and budget cuts from the NIH are causing government-sponsored grants to become more competitive than ever. With OpenClinica, we are able to put in place an enterprise-quality, regulatory compliant electronic data capture and clinical data management system that will make us more attractive to both government-sponsored and industry-sponsored clinical trials.”
In addition to its regulatory compliance capabilities, MICHR cited OpenClinica’s flexibility to support a wide variety of studies off the same platform, thereby increasing the institute’s efficiency. This efficiency will serve MICHR well in its support of a large and growing number of diverse clinical studies.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.